Development or exacerbation of hidradenitis suppurativa in two transgender men after initiation of testosterone therapy.

Development or exacerbation of hidradenitis suppurativa in two transgender men after initiation of testosterone therapy. Br J Dermatol. 2021 Jan 15;: Authors: Buonomo M, Mansh MD, Thorpe D, Goldfarb N Abstract Transgender individuals are a growing patient population with unique dermatologic needs. Masculinizing hormone therapy (MHT) involves the use of exogenous testosterone to promote masculine and suppress feminine secondary sex characteristics.1 Commonly reported cutaneous effects of MHT include acne vulgaris and androgenic alopecia.2 To our knowledge, there have been no reported cases of hidradenitis suppurativa (HS) among transgender patients receiving MHT. Herein we present two patients, one that developed HS and one with worsening HS symptoms after initiating MHT. PMID: 33448331 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research